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Abstract
Cancer survivors have a higher risk of new primary cancer, in the same or in another organ, than the general
population. We report a 78-year-old women who has metachronous quadruple adenocarcinoma, includes bilateral
breast cancer, ovarian cancer and retroperitoneal neuroendocrine carcinoma. The development of second cancer in
cancer survivors can be expected but third or higher order malignancies are rare.
Introduction
Cancer survivors are a growing group owing to
improvements in widely scanning and treatment. In this
group the most serious event is the diagnosis of a new
second cancer. Also older people population increases.
Thus two reasons occurrence of multiple primary can-
cers are likely to increase.
Cancer patients have a 20% higher risk of new primary
cancer, in the same organ or in another organ, com-
pared with the general population. Also, second cancers
have become a leading cause of death among long-term
cancer survivors [1]. Individual susceptibility factors
remain largely unknown but, it may not necessarily be
attributable solely to prior cancer treatment but may
also reflect the effect of shared etiologic factors, envir-
onmental exposures and inherited predisposition. Multi-
ple cancers, two or more primary cancers, were defined:
each of the tumors must present a definite pattern of
malignant disease, each must be distinct, and the possi-
bility that one tumor is a metastasis of the other must
be excluded since 1932 [2].
In cancer survivors, the number of second- or higher-
order cancers is burgeoning and accounted for about
16% of incident cancers in 2003 [3]. The development
of second cancer in cancer survivor is expected but
third, or higher order malignancies are rare. To our
knowledge, this is the first detected case with this com-
bination of primary adenocarcinomas.
Case
A 78-year-old patient who had metachronous quadruple
cancer was admitted to our clinic. In her family history;
her grandmother had lung cancer. She had undergone
right modified radical mastectomy for invasive breast
cancer (Fig. 1-A) in 1996. After adjuvant chemotherapy
and radiotherapy she treated with hormone therapy as
tamoxifen. After two years, in 1998, she had undergone
total abdominal hysterectomy, bilateral salphingoopher-
ectomy (TAH&BSO) and partial omentectomy for her
right ovarian mass. Pathologic examination showed
poorly differentiated serous carcinoma (Fig. 1-B). No
metastasic lesion was detected. She treated with com-
bined paclitaxel and cisplatin regimen for 6 cycles.
Then, she was followed-up without any sign of recur-
rence. She felt accidentally a lump of the left breast so
she had visited a hospital for a work-up in 2006. The
detailed examination proved that the intraductal carci-
noma (Fig. 1-C) in left breast mass was primary breast
cancer so the right modified radical mastectomy was
carried out and pathologic examination showed intra-
ductal carcinoma. Hormone receptor status was nega-
tive. She did not have any adjuvant treatment. Lobular
border solid mass in left renal hilus was detected by
abdominal computerized tomography (CT). Trucut
biopsy was done and pathologic examination showed
undifferantiate neuroendocrine carcinoma (Fig. 1-D). In
the surgery abdominal aorta was surrounded by tumor
in pancreas tail. It was accepted as in-operabl. She was
treated with combined cisplatin and etoposid che-
motherapy regimen. After 3 cycles response was evalu-
ated as partial response and stable disease after 5 cycles
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any medium, provided the original work is properly cited.of chemotherapy. In August 2008, her clinical status was
deterioted and detected as progressive disease and com-
bination carboplatin and etoposide regimen was
administered.
Discussion
We report an unusual case of metachronous quadruple
which were all adenocarcinomas. She had undergone
surgery and combined chemotherapy for these cancers.
Multiple primary malignancies are common, in a study
encountered in 3-5% of malignant tumors which are
most often secondary, triple tumors occur in only 0.5%,
quadruple tumors in 0.3% of malignant tumors [4]. Our
patient has a quadruple cancer accordingly Agency for
Research on Cancer (IARC) but not according to Sur-
veillance Epidemiology and End Results (SEER) rules.
Contralateral malignant lesions of the breast are consid-
ered as subsequent primary tumours according to SEER
rules [5].
The increased risk of subsequent malignancies among
cancer survivors is well-established and initially diag-
nosed with cancer ages 30 to 49. Second primary
cancers can be examined into three categories; therapy
releated, syndromic and those resulting from shared
etiologic influences by Travis et al [6]. SEER program
data were diagnosed with a second cancer by 25 years
follow-up for patients who have already developed a sec-
ond malignancy, recognition of the types of possible
additional malignancies, the associated latency periods,
and underlying risk factors such as treatment, genetic
predisposition, environmental cofactors will have impor-
tant implications for follow-up and screening. In general
second malignancies are a result of success and are not
observed unless a patient survives an initial cancer diag-
nosis [3].
Deligdisch et al. analyzed that 67 (5.4%) cases of mul-
tiple primary malignancieso ft h eg e n i t a lo r g a n sa n d
breast in their different combinations in 1235 multiple
primary malignancies. A higher incidence of multiple
primary cancers were found in embryologically related
organs such us endometrium and ovary [7]. Similar
results were reported as the most frequent organ
involved in multiple tumors was breast, the largest
amount of data exist for contralateral breast cancer,
Figure 1 A-Invazive ductal carcinoma; Glandular differentiation is apparent as tubular structures with central lumina. A proportion of
tumour cells are arranged in cords, clusters and trabeculae (HE ×10), B- Poorly differentiated serous carcinoma glandular and papillary
architecture of tumour. The glands are typically irregular and slit-like (HE ×10), C- Intraductal carcinoma with cribriform and micropapillary
pattern (HE ×40), D- Undifferantiate neuroendocrine carcinoma; sheets of polygonal, round cells with salt and pepper nuclei and numerous
mitotic figures (HE ×10).
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tors. Like in our patient association breast and ovarian
cancers are likely due to genetic factors and hormonal
influences. Cancer treatment (chemotherapy and radio-
therapy) and insufficient hormone therapy may cause
contralateral breast cancer in our case. However familial
cancer syndrome should be thought because of combi-
nations of ovarian and breast cancer, although our case
had no evident family history of cancer.
Watanabe et al. analyzed multiple primary malignan-
cies in 285 (5.2%) double primary cancers, 58 (1.1%) tri-
ple or more in 5,456 consecutive autopsy cases [8]. In
Antal et al.’s study with 719 cancer patients, multiple
malignancies were found in 53 cases (7.4%). 49 of these
being second malignancy and 4 were third malignancy.
Colorectal and gynecological malignancies appeared
with breast cancer in 5 cases [9]. Ng et al. reported 181
patients second malignancies in 1,319 Hodgkin lym-
phoma patients. From these, 18 ot them developed a
third malignancy, especially breast cancers, lung cancers
and genitourinary cancers. The median time between
the development of the second and third malignancy
was 34 months [10]. Bhatia et al. described 141 patients
developed 1 subsequent malignancy, 26 patients devel-
oped 2 subsequent malignancies, 5 patients developed 3
subsequent malignancies, and one patient developed 4
subsequent malignancies among 1,380 childhood cancer
survivors. The third neoplasms included 28 solid malig-
nancies, 1 hematologic malignancy. The estimated 10-
year cumulative incidence of developing a third malig-
nancy was 21% from the time of diagnosis of the second
malignancy [11]. Latent period between second and
third malignancies was 8 years. Our case was not similar
to data in the literature for this reason.
In our patient, Neuroendocrine tumors (NET) was the
forth developed cancer and they are frequently asso-
ciated with synchronous or metachronous secondary
malignancies. Progemmer et al. showed that 14 patients
with NET and secondary malignancies from a series of
96 patients with NET. The median age of the patients at
diagnosis of NET was 69 years (range: 56-86 yrs). 5
patients had synchronous secondary malignancies and 9
metachronous secondary malignancies [12].
Our case has metachronous quadruple adenocarcino-
mas and she may develop fifth or more malignancy in
the following times. In conclusion, we need an improve-
ment for our knowledge of the risks and patterns of
high-order malignancies.
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